Two Sigma Investments LP purchased a new stake in Horizon Pharma PLC (NASDAQ:HZNP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,151 shares of the biopharmaceutical company’s stock, valued at approximately $310,000.
Several other hedge funds also recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its stake in shares of Horizon Pharma PLC by 0.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 120,714 shares of the biopharmaceutical company’s stock valued at $1,954,000 after buying an additional 800 shares in the last quarter. Boston Advisors LLC boosted its position in Horizon Pharma PLC by 7.3% in the third quarter. Boston Advisors LLC now owns 24,125 shares of the biopharmaceutical company’s stock valued at $437,000 after buying an additional 1,640 shares during the last quarter. California State Teachers Retirement System boosted its position in Horizon Pharma PLC by 0.9% in the third quarter. California State Teachers Retirement System now owns 341,833 shares of the biopharmaceutical company’s stock valued at $6,197,000 after buying an additional 3,000 shares during the last quarter. BlackRock Investment Management LLC boosted its position in Horizon Pharma PLC by 0.8% in the third quarter. BlackRock Investment Management LLC now owns 605,733 shares of the biopharmaceutical company’s stock valued at $10,982,000 after buying an additional 4,953 shares during the last quarter. Finally, KCG Holdings Inc. boosted its position in Horizon Pharma PLC by 28.3% in the third quarter. KCG Holdings Inc. now owns 40,240 shares of the biopharmaceutical company’s stock valued at $730,000 after buying an additional 8,875 shares during the last quarter. Institutional investors own 88.09% of the company’s stock.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded up 0.53% on Thursday, hitting $15.28. 519,887 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $15.05 and its 200 day moving average price is $16.97. The stock’s market cap is $2.48 billion. Horizon Pharma PLC has a 12-month low of $13.05 and a 12-month high of $23.44.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, February 27th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.13. The firm had revenue of $310.30 million for the quarter, compared to analysts’ expectations of $307.93 million. Horizon Pharma PLC had a negative net margin of 1.34% and a positive return on equity of 22.73%. The firm’s quarterly revenue was up 26.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. On average, equities analysts predict that Horizon Pharma PLC will post $2.16 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “19,151 Shares in Horizon Pharma PLC (HZNP) Acquired by Two Sigma Investments LP” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.chaffeybreeze.com/2017/04/20/two-sigma-investments-lp-acquires-shares-of-19151-horizon-pharma-plc-hznp-updated.html.
A number of brokerages recently commented on HZNP. Mizuho reaffirmed a “buy” rating and issued a $25.00 target price on shares of Horizon Pharma PLC in a report on Wednesday, February 22nd. Zacks Investment Research raised Horizon Pharma PLC from a “sell” rating to a “hold” rating in a report on Friday, February 17th. Morgan Stanley reissued an “equal weight” rating and set a $20.00 price target on shares of Horizon Pharma PLC in a report on Tuesday, February 28th. Guggenheim began coverage on Horizon Pharma PLC in a research report on Monday, February 27th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Jefferies Group LLC set a $26.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research note on Wednesday, April 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $28.00.
In related news, EVP Robert Carey sold 31,808 shares of the company’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $16.03, for a total value of $509,882.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.10% of the company’s stock.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.